First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors.Yakun Wang, Lin Shen, Ling Lin et al.|Journal of Clinical Oncology|2023Cited by 32
Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trialHongzhou Lu, Nanshan Zhong, George Zhang et al.|EClinicalMedicine|2024Cited by 23
Nicotinic Acid against Acetaminophen-Induced Hepatotoxicity via Sirt1/Nrf2 Antioxidative Pathway in MiceHu Da, Longjiang Li, Li Zhang et al.|Journal of Nutritional Science and Vitaminology|2021Cited by 20
Janus kinase inhibitor Tofacitinib alleviated acute hepatitis induced by lipopolysaccharide/D-galactosamine in miceXinyue Zhang, Yongqiang Yang, Ling Lin et al.|Molecular Biology Reports|2022Cited by 2
JAK inhibitor Tofacitinib alleviated acute hepatitis induced by lipopolysaccharide/D-galactosamine in miceXinyue Zhang, Yongqiang Yang, Ling Lin et al.|Research Square|2022Cited by 0